Nephrogen
Curative genetic medicines for kidney diseases
Nephrogen is a Stanford biotech spin-out developing curative genetic medicines for kidney and pancreatic diseases. Kidney disease alone affects 1 in 7 Americans, and neither indication has any approved gene-based therapies. Nephrogen's underlying platform combines AI and high-throughput screening to engineer safer, more efficient, and less expensive gene delivery vehicles for reaching the kidney and pancreas, and has attracted non-dilutive funding from seven major pharmaceutical companies including Merck KGaA, Novartis, and Bristol Myers Squibb.
- Website
- nephrogenbiotech.com
- City
- New York City
- Country
- United States
- YC batch
- Summer 2020
- Team
- 5 people
- Stage
- Early stage
- AI-native
- Yes
More Health & bio in New York City
Ro$5bn
Health technology. Valued at $5bn (March 2021).
Noom$3.7bn
Healthcare. Valued at $3.7bn (May 2021).
Headway$2.3bn
Healthcare. Valued at $2.3bn (July 2024).
Sword Health$2bn
Health. Valued at $2bn (November 2021).
H1
Connecting stakeholders across the healthcare ecosystem.
Opentrons
We make robots for biologists.
Claim this profile
Free and instant: prove you run nephrogenbiotech.com and edit the profile yourself.
- Your logo, office address and founder photos
- The ✓ Verified mark next to Nephrogen across the site
- Open roles listed on the Hiring board
- A followed link back to your website
A rank card with Nephrogen's standing on Labspie, or a simple badge. Both link to this profile and update themselves.
